Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer

S. Tumolo, G. Toffoli, S. Saracchini, G. Lo Re, G. Bruschi, M. G. Boccieri

Research output: Contribution to journalArticlepeer-review

Abstract

In the last years, the main topoisomerase I inhibitors (TP1-I) (i.e. topotecan and irinotecan) have been used in combination chemotherapy in non-small cell lung cancer. Several drugs (also alternative to cisplatin) have been used in combination with TP1-I, but to date the higher remission rate obtained with combinations is not translated into a more prolonged survival in comparison with TP1-I given alone. On the other hand, the toxicity of TP1-I combinations is greater than those of TP1-I used alone. The superior efficacy of combinations versus TP1-I used alone remains an open question. Furthermore, the best schedule for TP1-I has not been completely elucidated. Randomised studies are few (only two phase III trials) and only controlled studies will be able to clarify the best TP1-I combination regimen.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalLung Cancer
Volume34
Issue numberSUPPL. 4
Publication statusPublished - 2001

Keywords

  • Combination chemotherapy
  • Efficacy
  • Irinotecan
  • Non-small cell lung cancer
  • Topoisomerase inhibitors
  • Topotecan
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this